FT Markets

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer ...

In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary endpoint of overall survival (OS), with the ivonescimab plus chemotherapy ...

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression ...
BIOENGINEER

Traditional Medicinal Liquor Eases Rheumatoid Arthritis in Rats, With Isoimperatorin Flagged as Key Active Compound

A traditional Chinese medicinal liquor formula and its constituent isoimperatorin reduced joint inflammation and tissue ...
oncodaily

ROSETTA Lung-107: Pumitamig Plus Docetaxel Shows Early Activity After Chemoimmunotherapy in Metastatic NSCLC

ROSETTA Lung-107 shows pumitamig plus docetaxel achieved 36.7% ORR and 6.9-month PFS after chemoimmunotherapy in metastatic NSCLC.
quiverquant

BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Results for Pumitamig Plus Docetaxel in Previously Treated Non-Small Cell Lung Cancer

Pumitamig plus docetaxel demonstrated a confirmed objective response rate of 36.7% in patients with non-small cell lung ...